Proteomics International Laboratories (PIQ) AGM 2024 presentation summary

Business overview and strategy

• Focuses on predictive diagnostics and precision medicine, commercializing three first-in-class tests: PromarkerD (diabetic kidney disease), PromarkerEndo (endometriosis), and PromarkerEso (esophageal cancer).

• Proprietary Promarker platform enables identification of unique protein biomarkers for novel diagnostic tests.

• Hybrid go-to-market strategy includes both traditional licensing to labs and direct-to-patient/consumer pathways, leveraging telehealth and digital marketing.

• Revenue-generating bioanalytical services help offset cash burn; current revenue excludes Promarker test sales.

• Board renewal and recruitment of senior executives underway to accelerate commercialisation.

Financial and corporate highlights

• Market capitalization of A$91m, cash of ~A$5.1m as of 30 Sept 2024, and A$2.7m revenue for FY25.

• Institutional placement raised $6.5m in January 2024, with strong participation from Asian and Australian funds.

• Top 40 shareholders hold 41% of shares; directors hold 14%.

• Accredited laboratories and specialist proteomics technology platform headquartered in Perth, WA.

Product pipeline and clinical validation

• PromarkerD: Predicts onset of chronic kidney disease in diabetes up to 4 years in advance, 86% accuracy, US reimbursement price set at $390.

• PromarkerEndo: World-first blood test for endometriosis, ~90% accuracy, targeting launch in Australia Q2 CY25.

• PromarkerEso: Blood test for esophageal cancer, 94% accuracy, targeting launch in Australia Q1 CY25.

• OxiDx: Late-stage development of a blood test for oxidative stress, with applications in sports and animal health.